Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05686226 · ClinicalTrials.gov registry record · Phase 2
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
A Phase 2 study of Cervical Cancer and Metastatic Cancer, sponsored by Christian Hinrichs.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT05686226 is a Phase 2 study of Cervical Cancer and Metastatic Cancer that is actively recruiting participants, run by Christian Hinrichs. The registered enrollment target is 20 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05686226, a Phase 2 study of Cervical Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Christian Hinrichs.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.
Conditions Studied
Interventions
- DRUG Aldesleukin
- BIOLOGICAL E7 TCR-T cells
Study Locations (3)
New Jersey
- Rutgers Cancer Institute - New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital - New Brunswick
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05686226
The ClinicalTrials.gov registry entry for NCT05686226 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Christian Hinrichs, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Aldesleukin is the first listed.
NCT05686226 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Maryland.
Frequently Asked Questions
What is clinical trial NCT05686226 about?
NCT05686226 is a clinical study titled "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers". This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR...
What is the current status of trial NCT05686226?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-03-07. Estimated completion is 2027-01-01.
What conditions does trial NCT05686226 study?
This clinical trial studies the following conditions: Cervical Cancer, Metastatic Cancer, Oropharynx Cancer, Anal Cancer, Vaginal Cancer.
What interventions are being tested in trial NCT05686226?
The interventions under investigation include: Aldesleukin (DRUG), E7 TCR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05686226?
This trial is sponsored by Christian Hinrichs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05686226 being conducted?
This trial has 3 study locations across Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.